PMC:7461420 / 99885-100693 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":0,"end":4},"obj":"Body_part"},{"id":"T2","span":{"begin":575,"end":583},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24985"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma82768"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T496","span":{"begin":540,"end":559},"obj":"Disease"},{"id":"T498","span":{"begin":649,"end":653},"obj":"Disease"}],"attributes":[{"id":"A496","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A497","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0006517"},{"id":"A498","pred":"mondo_id","subj":"T498","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":21,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":144,"end":145},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":292,"end":300},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T4","span":{"begin":419,"end":427},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T5","span":{"begin":466,"end":467},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":564,"end":567},"obj":"http://purl.obolibrary.org/obo/CLO_0009132"},{"id":"T7","span":{"begin":797,"end":807},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T88002","span":{"begin":74,"end":83},"obj":"Chemical"},{"id":"T9851","span":{"begin":101,"end":110},"obj":"Chemical"},{"id":"T67871","span":{"begin":224,"end":238},"obj":"Chemical"},{"id":"T12849","span":{"begin":255,"end":269},"obj":"Chemical"},{"id":"T13","span":{"begin":474,"end":482},"obj":"Chemical"},{"id":"T63941","span":{"begin":483,"end":487},"obj":"Chemical"},{"id":"T81847","span":{"begin":575,"end":583},"obj":"Chemical"},{"id":"T1649","span":{"begin":787,"end":796},"obj":"Chemical"}],"attributes":[{"id":"A91536","pred":"chebi_id","subj":"T88002","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A23557","pred":"chebi_id","subj":"T9851","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A25183","pred":"chebi_id","subj":"T67871","obj":"http://purl.obolibrary.org/obo/CHEBI_35476"},{"id":"A10001","pred":"chebi_id","subj":"T12849","obj":"http://purl.obolibrary.org/obo/CHEBI_35469"},{"id":"A80897","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A10722","pred":"chebi_id","subj":"T63941","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A76307","pred":"chebi_id","subj":"T81847","obj":"http://purl.obolibrary.org/obo/CHEBI_18186"},{"id":"A61261","pred":"chebi_id","subj":"T1649","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3082","span":{"begin":129,"end":137},"obj":"Species"},{"id":"3083","span":{"begin":636,"end":640},"obj":"Species"},{"id":"3084","span":{"begin":649,"end":657},"obj":"Species"},{"id":"3085","span":{"begin":676,"end":685},"obj":"Species"},{"id":"3086","span":{"begin":706,"end":710},"obj":"Species"},{"id":"3087","span":{"begin":410,"end":418},"obj":"Species"},{"id":"3088","span":{"begin":338,"end":349},"obj":"Chemical"},{"id":"3089","span":{"begin":540,"end":559},"obj":"Disease"}],"attributes":[{"id":"A3082","pred":"tao:has_database_id","subj":"3082","obj":"Tax:1335626"},{"id":"A3083","pred":"tao:has_database_id","subj":"3083","obj":"Tax:11118"},{"id":"A3084","pred":"tao:has_database_id","subj":"3084","obj":"Tax:694009"},{"id":"A3085","pred":"tao:has_database_id","subj":"3085","obj":"Tax:11137"},{"id":"A3086","pred":"tao:has_database_id","subj":"3086","obj":"Tax:11135"},{"id":"A3087","pred":"tao:has_database_id","subj":"3087","obj":"Tax:1335626"},{"id":"A3088","pred":"tao:has_database_id","subj":"3088","obj":"MESH:C515233"},{"id":"A3089","pred":"tao:has_database_id","subj":"3089","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}

{"project":"LitCovid-sentences","denotations":[{"id":"T883","span":{"begin":0,"end":138},"obj":"Sentence"},{"id":"T884","span":{"begin":139,"end":337},"obj":"Sentence"},{"id":"T885","span":{"begin":338,"end":459},"obj":"Sentence"},{"id":"T886","span":{"begin":460,"end":610},"obj":"Sentence"},{"id":"T887","span":{"begin":611,"end":753},"obj":"Sentence"},{"id":"T888","span":{"begin":754,"end":808},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Shin et al. analyzed a library of 2334 approved medications and bioactive molecules to find possible antiviral compounds against MERS‐CoV. 259 A series of hit compounds was identified, categorized as anticancer (189, 190), antipsychotics (191, 192), and antidepressant (193) with inhibition activity between 2.1 and 14.4 µM (Figure 38). Saracatinib (189) was especially interesting, as it had remarkable anti‐MERS‐CoV activity (EC50 of 2.9 µM, CC50 \u003e 50 µM). It is a small molecule drug with oral bioavailability used in the management of malignant neoplasms via Src‐family tyrosine kinases (SFKs) inhibition. It also suppressed other CoVs such as SARS‐CoV‐1 (EC50, 2.4 µM), HCoV‐229E (EC50, 5.1 µM), and FIPV (EC50, 7.0 µM) at nontoxic concentrations. Drugs 190 to 193 showed moderate antiviral activities."}